Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Rethinking On-Target Off-Tumor Toxicity as a Hematopoietic Continuum.

European journal of haematology·2026
Same author

Mechanisms of post-transplant AML relapse and therapeutic implications.

Bone marrow transplantation·2026
Same author

PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression.

Cancer gene therapy·2026
Same authorSame journal

Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.

European journal of haematology·2026
Same author

Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.

Apoptosis : an international journal on programmed cell death·2026
Same author

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Related Experiment Video

Updated: Jun 12, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Alessandro Corso1, Monia Marchetti2, Monica Galli3

  • 1Hematology and Stem Cell Transplantation Division, Hospital Legnano, Legnano, Italy.

European Journal of Haematology
|January 15, 2026
PubMed
Summary

Suboptimal imaging for myeloma (plasma cell disorders) leads to under-recognition of lesions and impacts treatment. This study developed evidence-based, country-specific imaging recommendations for Italy to improve patient care.

Keywords:
MGUSMRI DWIPET/CTbone diseasemyelomawhole‐body LDCT

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

Area of Science:

  • Hematology
  • Radiology
  • Oncology

Background:

  • Suboptimal imaging modalities hinder accurate detection of bone and extra-bone myeloma lesions.
  • This impacts disease status recognition and timely treatment decisions for plasma cell disorders (PCD).
  • A lack of systematic evidence review accompanied previous recommendations.

Purpose of the Study:

  • To evaluate current real-world imaging practices in Italy for PCD.
  • To identify factors and barriers affecting the adoption of international imaging guidelines.
  • To create evidence-based, country-specific recommendations for PCD imaging assessment.

Main Methods:

  • A national project initiated in 2024 involved 32 hematology centers and 5 radiology services.
  • A survey assessed current practices and barriers.
  • A Delphi panel of 23 experts achieved consensus on 25 recommendations.

Main Results:

  • Survey data confirmed that suboptimal imaging modalities significantly contribute to under-recognized bone and extra-bone lesions.
  • This leads to inaccurate disease staging and suboptimal treatment planning.
  • Challenges in adopting international guidelines were identified.

Conclusions:

  • Effective imaging is crucial for improving PCD detection and guiding treatment.
  • The study successfully developed country-specific, evidence-based imaging recommendations for Italy.
  • These recommendations aim to overcome barriers and enhance the adoption of international guidelines.